<DOC>
	<DOCNO>NCT00821912</DOCNO>
	<brief_summary>This open label , non-randomised , multicentre phase 1-2 study fix dose Taxotere combination Xeloda dose escalate first phase study ( modify Fibonacci design ) fix second phase . The primary objective phase 1 part define dose recommend Phase II part study . The primary objective determine response rate .</brief_summary>
	<brief_title>TaxXel : Taxotere Xeloda Esophageal Cancer</brief_title>
	<detailed_description />
	<mesh_term>Esophageal Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Histologically confirm squamous cell carcinoma adenocarcinoma oesophagus cardia . Inoperable metastatic disease Performance status ( WHO ) 02 Measurable disease . Adequate hematological , liver renal function . Signed informed consent . CNS metastases Symptomatic peripheral neuropathy equal great NCI grade 2 . Other concomitant serious illness medical condition . Past current history malignant neoplasm oesophageal carcinoma . &lt; 18 year age . Pregnant lactating patient .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2012</verification_date>
</DOC>